MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer

22Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer with poor prognosis due to lack of druggable targets such as hormone and growth factor receptors. Therefore, identification of targetable regulators such as miRNAs could provide new avenues for therapeutic applications. Here, we report that the expression of miR-4417 is suppressed during the progression of TNBC cells from non-malignant to the malignant stage. MiR-4417 is localized to chromosome 1p36, a region with high frequency of loss of heterozygosity in multiple cancers, and its biogenesis is DICER-dependent. Low expression of miR-4417 is significantly associated with worse prognosis in TNBC patients, while overexpression of miR-4417 is sufficient to inhibit migration and mammosphere formation of TNBC cells in vitro. Overall, our findings suggest miR-4417 exerts a tumor suppressive effect and thereby could serve as a prognostic biomarker and therapeutic tool against TNBC.

Cite

CITATION STYLE

APA

Wong, C. K., Gromisch, C., Ozturk, S., Papageorgis, P., Abdolmaleky, H. M., Reinhard, B. M., … Thiagalingam, S. (2019). MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer. Cancer Biology and Therapy, 20(8), 1113–1120. https://doi.org/10.1080/15384047.2019.1595285

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free